Cyclerion Therapeutics (CYCN) EBT Margin (2019 - 2025)
Historic EBT Margin for Cyclerion Therapeutics (CYCN) over the last 6 years, with Q3 2025 value amounting to 114.97%.
- Cyclerion Therapeutics' EBT Margin rose 4664700.0% to 114.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 127.25%, marking a year-over-year increase of 29268700.0%. This contributed to the annual value of 181.4% for FY2024, which is N/A changed from last year.
- Per Cyclerion Therapeutics' latest filing, its EBT Margin stood at 114.97% for Q3 2025, which was up 4664700.0% from 1797.85% recorded in Q2 2025.
- Cyclerion Therapeutics' EBT Margin's 5-year high stood at 27.8% during Q4 2024, with a 5-year trough of 21604.84% in Q1 2021.
- Over the past 4 years, Cyclerion Therapeutics' median EBT Margin value was 1798.77% (recorded in 2025), while the average stood at 3505.29%.
- As far as peak fluctuations go, Cyclerion Therapeutics' EBT Margin crashed by -196099700bps in 2021, and later skyrocketed by 197786800bps in 2022.
- Over the past 4 years, Cyclerion Therapeutics' EBT Margin (Quarter) stood at 2690.06% in 2021, then tumbled by -63bps to 4389.87% in 2022, then skyrocketed by 101bps to 27.8% in 2024, then plummeted by -514bps to 114.97% in 2025.
- Its EBT Margin was 114.97% in Q3 2025, compared to 1797.85% in Q2 2025 and 1798.77% in Q1 2025.